Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01785849 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Etelcalcetide (AMG 416) in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease on Hemodialysis
A Phase 3 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 3
- Development phase
- 508
- Enrollment target
NCT01785849 is a Phase 3 study that has completed, run by Amgen. The registered enrollment target is 508 participants.
The verdict
NCT01785849, a Phase 3 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 508 participants
- Enrollment target
Study Summary
This study is designed to assess the efficacy and safety of etelcalcetide compared with placebo in the treatment of SHPT in patients with chronic kidney disease (CKD) receiving hemodialysis.
Interventions
- DRUG Placebo
- DRUG Etelcalcetide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 508 participants |
| Start Date | 2013-03-12 |
| Est. Completion | 2014-06-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01785849
The ClinicalTrials.gov registry entry for NCT01785849 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 508 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01785849 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01785849 about?
NCT01785849 is a clinical study titled "Efficacy and Safety of Etelcalcetide (AMG 416) in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease on Hemodialysis". This study is designed to assess the efficacy and safety of etelcalcetide compared with placebo in the treatment of SHPT in patients with chronic kidney disease (CKD) receiving hemodialysis.
What is the current status of trial NCT01785849?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 508 participants. The study started on 2013-03-12. Estimated completion is 2014-06-12.
What interventions are being tested in trial NCT01785849?
The interventions under investigation include: Placebo (DRUG), Etelcalcetide (DRUG).
Who is sponsoring clinical trial NCT01785849?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.